Download PDF: New Long-Acting Reversible Contraception Option
Jaydess is a new option in intra-uterine contraception which adds to the other available option Mirena. The rationale for the development of Jaydess is a shorter maximum duration of use and a lower daily levonorgestrel release rate, which result in a smaller reservoir and therefore an easier and less painful placement.
Jaydess – Small T-body with narrow insertion tube and low dose
| Jaydess | Mirena | |
| T-frame dimension | 28mmx30mm, including silver ring | 32mmx32mm |
| Insertion tube diameter | 3.80mm (with Evolnserter) | 4.4mm (with Evolnserter) |
| Initial in vivo LNG release rate | 6µg/day (average over 3 years) | 20µg/day (not same timepoint or calculation model) |
| Maximum duration of use | 3 years | 5 years |
| Total LNG content | 13.5mg | 52mg |
LNG: levonorgestrel
Study Results
Phase III study of 2,884 women aged 18-35 comparing Jaydess with another low dose intra-uterine system1
Phase II study of 742 women aged 21-40 comparing Jaydess and Mirena2
|
*Pearl Index: Number of failures per 100 woman years of exposure
Conclusion
Dr Daragh O’Neill, GP, with a specialist interest in women’s health and tutor in contraception, commented on the results: “In Ireland, Mirena has been used mainly by women over 35 years, so a smaller, lower-dose device could suit a larger range of women, including the younger woman”.
See also:
Long-Acting Reversible Contraception
References:
1- Nelson A, Apter D, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013 Dec;122(6):1205-13.
2- Gemzell-Danielsson K1, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012 Mar;97(3):616-22.
More on Contraception: